NCT01913067View on ClinicalTrials.gov

Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

September 30, 2016

Conditions
Brain MetastasisBreast CancerNon Small Cell Lung Cancer
Interventions
DRUG

Cabazitaxel

Intravenous, 25 mg/m2 every 3 weeks

PROCEDURE

Contrast-enhanced whole brain MRI

Evaluation of the volumetric reduction in the size of the brain lesion(s).

Trial Locations (1)

1000

Institut Jules Bordet, Brussels

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Jules Bordet Institute

OTHER